• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center



The primary objective of the Dana-Farber/Harvard Cancer Center (DF/HCC) prostate cancer SPORE is to focus on central clinical questions in the field of prostate cancer. Reflecting an advancement of knowledge gained from our last SPORE project period, basic, clinical, and translational investigators from Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, the Broad Institute of Harvard and MIT, Harvard School of Public Health, Massachusetts General Hospital, and Massachusetts Institute of Technology have joined together with the following goals:

  • Define and characterize germline genetic variations, somatic mutations as well as environmental factors leading to the pathogenesis and identification of “aggressive” prostate cancer
  • Develop a better understanding of androgen signaling and develop therapies directed at this pathway while minimizing side effects
  • Improve prostate cancer treatment through better use of individual clinical and molecular characteristics to select or refine treatment  and by the introduction of genetically-based and other novel therapeutic strategies


Project 1: Tumor and circulating markers as links between obesity and lethal prostate cancer
Project 2: Gleason-based mRNA and metabolomic profiling to predict prostate cancer progression
Project 3: Genomic determinants of resistance to primary androgen deprivation therapy and aggressive disease
Project 4: Targeting Mechanisms Driving AR Activity in Advanced CRPC


Core A: Administration Core
Core B: Biostatistics and Computational Biology Core
Core C: Tissue and Pathology Core

Prostate Cancer SPORE Principal Investigator: Philip Kantoff, MD (DFCI)